Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Potassium Acetate→

Potassium Acetate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
127-08-2
Molecular formula
C2H3KO2
Molecular weight
98.14 g/mol
Drug class
Potassium saltintravenous electrolyte replacement and alkalinising precursor
Mechanism of action
Dissociates to provide potassium ions, which are essential for resting membrane potential, neuromuscular transmission and cardiac conduction. Acetate is metabolised to bicarbonate and can contribute to alkalinisation.
Indications / reported uses
  • Prevention and treatment of potassium depletion when intravenous replacement is indicated, particularly when chloride administration is undesirable; dose and infusion rate require electrolyte and cardiac monitoring

Sources: US DailyMed — Potassium acetate injection · NLM MeSH — Potassium acetate · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Potassium salt; intravenous electrolyte replacement and alkalinising precursor

Mechanism of action

Dissociates to provide potassium ions, which are essential for resting membrane potential, neuromuscular transmission and cardiac conduction. Acetate is metabolised to bicarbonate and can contribute to alkalinisation.

General use cases

  • Prevention and treatment of potassium depletion when intravenous replacement is indicated, particularly when chloride administration is undesirable; dose and infusion rate require electrolyte and cardiac monitoring

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Potassium Acetate Environmental Risk Assessment (ERA) (the Potassium Acetate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.